Selective Serotonin Reuptake Inhibitors for Late-Life Depression
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (5), 355-368
- https://doi.org/10.2165/00002512-200118050-00006
Abstract
Late-life depression is a serious health problem that is challenging to manage but generally responds well to pharmacotherapy. Selective serotonin (5-hydroxy-tryptamine; 5-HT) reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants, are usually used as first-line agents for elderly patients with depression. Like most drugs, SSRIs have not been widely tested in clinical trials that approximate ‘real-life’ geriatric situations. However, studies completed to date provide valuable information about the efficacy, safety and tolerability of this class of antidepressants among older patients with depression, including those with depression secondary to stroke or dementia and those with other comorbid physical disorders. Although one SSRI may be more efficacious or better tolerated by elderly patients than another, existing data do not support such claims. However, other distinguishing features may influence the choice of agent. For example, fluoxetine, fluvoxamine and paroxetine are more likely to be involved in significant drug-drug interactions than are citalopram or sertraline. In contrast to the other SSRIs, fluoxetine has a half-life well in excess of 1 day, which can be an advantage when weaning the patient off therapy in that it may reduce the incidence of discontinuation symptoms, but a significant disadvantage if the patient cannot tolerate the drug or experiences an adverse drug-drug interaction.Keywords
This publication has 81 references indexed in Scilit:
- Comparison of the tolerability and efficacy of citalopram and?amitriptyline in elderly depressed patients treated in general practiceDepression and Anxiety, 1998
- Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of DepressionPharmacoEconomics, 1998
- Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female VolunteersClinical Pharmacokinetics, 1997
- Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatientsInternational Clinical Psychopharmacology, 1996
- The effects of selective serotonin reuptake inhibitors and their metabolites on S‐mephenytoin 4'‐hydroxylase activity in human liver microsomes.British Journal of Clinical Pharmacology, 1995
- Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.Stroke, 1994
- A Double-Blind, Randomized, Fluoxetine-Controlled, Multicenter Study of Paroxetine in the Treatment of DepressionJournal of Clinical Psychopharmacology, 1993
- Clinical Pharmacokinetics of Selective Serotonin Reuptake InhibitorsClinical Pharmacokinetics, 1993
- CitalopramTherapeutic Drug Monitoring, 1993
- Double‐blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly peopleActa Psychiatrica Scandinavica, 1991